David J Nutt
Biographic Data
| ID | 4494560 |
|---|---|
| NAME | David J Nutt |
| GIVEN NAMES | David J |
| FAMILY NAME | Nutt |
| SIGNATURE | NUTT D J |
| AFFILIATIONS | Imperial College London |
| ORCID | 0000-0002-1286-1401 |
| VERIFIED | Yes |
| TOTAL WORKS | 23 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 23 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 1989 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Study protocol for “Psilocybin in patients with fibromyalgia: Brain biomarkers of action”
The results of this study will provide valuable insight into the brain mechanisms involved in the action of psilocybin-therapy for fibromyalgia with potential implications for the therapeutic action of psychedelic-therapy more broadly. It will also deliver essential data to inform the design of a potential subsequent RCT
Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder
The mechanisms by which Psilocybin Therapy (PT) improves depression remain an important object of study, with scientists actively exploring acute psychological experiences and neurobiological processes as candidates. In a phase 2, double-blind, randomized, active comparator controlled trial involving patients with moderate-to-severe major depressive disorder, we investigated whether acute psychological experiences could meaningfully account for t…
Psychedelics As Psychiatric Medications
Selective D3 receptor antagonism modulates neural response during negative emotional processing in substance dependence
Acute GSK598809 modulates the BOLD response to aversive image processing, providing evidence that D3 antagonism may impact emotional regulation. Enhanced BOLD response within D3-rich mesolimbic regions is consistent with its pharmacology and with attenuation of substance-related hypodopaminergic function. However, the lack of group differences in task-related BOLD response and the non-specific effect of GSK598809 between groups makes it difficult…
Comparison of food cue reactivity and eating behaviours in obesity, ex-smokers and abstinent alcohol dependence
Trial of Psilocybin versus Escitalopram for Depression
BACKGROUND: Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. METHODS: In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Patients were assigned in a 1:1 ratio…
Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”
Background: Anorexia nervosa (AN) is a serious and life-threatening psychiatric condition. With a paucity of approved treatments, there is a desperate need for novel treatment avenues to be explored. Here, we present (1) an overview of the ways through which Public Patient Involvement (PPI) has informed a trial of psilocybin-assisted therapy for AN and (2) a protocol for a pilot study of psilocybin-assisted therapy in AN currently underway at Imp…
A multi criteria decision analysis (MCDA) for evaluating and appraising government policy responses to non medical heroin use
Comparison of food cue reactivity and eating behaviours in obesity, ex-smokers and abstinent alcohol dependence
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression
Introduction: It is a basic principle of the ‘psychedelic’ treatment model that the quality of the acute experience mediates long-term improvements in mental health. In the present paper we sought to test this using data from a clinical trial assessing psilocybin for treatment-resistant depression (TRD). In line with previous reports, we hypothesized that the occurrence and magnitude of Oceanic Boundlessness (OBN) (sharing features with mystical-…
Using Baclofen to Explore Gaba-B Receptor Function in Alcohol Dependence: Insights From Pharmacokinetic and Pharmacodynamic Measures
Background: The role of GABA-B neurotransmission in addiction has recently received increased attention, with clinical trials indicating that baclofen, a GABA-B receptor agonist, may reduce alcohol consumption, craving and promote abstinence. However, the optimal dose to treat alcohol dependence is unclear with patients requesting and tolerating much higher doses of baclofen, compared with other clinical uses. We assessed the pharmacokinetics and…
A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation
The MCDA process allowed the participants to deconstruct complex drug policy issues into a set of simpler judgements that led to consensus about the results
Acute nutritional state and Body Mass Index influence Anterior Cingulate Cortex activation during motor response inhibition
Do Gut Hormones attenuate eating and addictive behaviours in obesity, alcohol and nicotine dependence
Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study
BACKGROUND: Psilocybin is a serotonin receptor agonist that occurs naturally in some mushroom species. Recent studies have assessed the therapeutic potential of psilocybin for various conditions, including end-of-life anxiety, obsessive-compulsive disorder, and smoking and alcohol dependence, with promising preliminary results. Here, we aimed to investigate the feasibility, safety, and efficacy of psilocybin in patients with unipolar treatment-re…
Estimating the Harms of Nicotine-Containing Products Using the MCDA Approach
Background: An international expert panel convened by the Independent Scientific Committee on Drugs developed a multi-criteria decision analysis model of the relative importance of different types of harm related to the use of nicotine-containing products. Method: The group defined 12 products and 14 harm criteria. Seven criteria represented harms to the user, and the other seven indicated harms to others. The group scored all the products on eac…
Medicina delle dipendenze
Alcohol and Relatively Pure Cannabis Use, but Not Schizotypy, are Associated with Cognitive Attenuations
Elevated schizotypy relates to similar cognitive attenuations as seen in psychosis and cannabis/polydrug use. Also, in schizotypal populations cannabis and polydrug (including licit drug) use are enhanced. These cognitive attenuations may therefore either be a behavioral marker of psychotic (-like) symptoms or the consequence of enhanced drug use in schizotypal populations. To elucidate this, we investigated the link between cognitive attenuation…
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Psychedelic drugs have a long history of use in healing ceremonies, but despite renewed interest in their therapeutic potential, we continue to know very little about how they work in the brain. Here we used psilocybin, a classic psychedelic found in magic mushrooms, and a task-free functional MRI (fMRI) protocol designed to capture the transition from normal waking consciousness to the psychedelic state. Arterial spin labeling perfusion and bloo…
Drug harms in the UK: A multicriteria decision analysis
The role and basis of the drug laws
On 30 October 2009, the home secretary in the UK asked David Nutt to resign from his post as chairman of the government's advisory council on the misuse of drugs. The previous day, the Centre for Crime and Justice Studies at King's College London had published Nutt's paper, ‘Estimating drug harms: a risky business?’. This is an edited version of his Eve Saville memorial lecture, delivered at Kings College in July 2009. The paper points out that e…
Development of a rational scale to assess the harm of drugs of potential misuse
Low affinity hypothalamic [3H]mazindol binding: A probe for hypothalamic body weight regulation
No prominent works on this page.
Low affinity hypothalamic [3H]mazindol binding: A probe for hypothalamic body weight regulation
Development of a rational scale to assess the harm of drugs of potential misuse
Drug harms in the UK: A multicriteria decision analysis
The role and basis of the drug laws
On 30 October 2009, the home secretary in the UK asked David Nutt to resign from his post as chairman of the government's advisory council on the misuse of drugs. The previous day, the Centre for Crime and Justice Studies at King's College London had published Nutt's paper, ‘Estimating drug harms: a risky business?’. This is an edited version of his Eve Saville memorial lecture, delivered at Kings College in July 2009. The paper points out that e…
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Psychedelic drugs have a long history of use in healing ceremonies, but despite renewed interest in their therapeutic potential, we continue to know very little about how they work in the brain. Here we used psilocybin, a classic psychedelic found in magic mushrooms, and a task-free functional MRI (fMRI) protocol designed to capture the transition from normal waking consciousness to the psychedelic state. Arterial spin labeling perfusion and bloo…
Estimating the Harms of Nicotine-Containing Products Using the MCDA Approach
Background: An international expert panel convened by the Independent Scientific Committee on Drugs developed a multi-criteria decision analysis model of the relative importance of different types of harm related to the use of nicotine-containing products. Method: The group defined 12 products and 14 harm criteria. Seven criteria represented harms to the user, and the other seven indicated harms to others. The group scored all the products on eac…
Medicina delle dipendenze
Alcohol and Relatively Pure Cannabis Use, but Not Schizotypy, are Associated with Cognitive Attenuations
Elevated schizotypy relates to similar cognitive attenuations as seen in psychosis and cannabis/polydrug use. Also, in schizotypal populations cannabis and polydrug (including licit drug) use are enhanced. These cognitive attenuations may therefore either be a behavioral marker of psychotic (-like) symptoms or the consequence of enhanced drug use in schizotypal populations. To elucidate this, we investigated the link between cognitive attenuation…
Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study
BACKGROUND: Psilocybin is a serotonin receptor agonist that occurs naturally in some mushroom species. Recent studies have assessed the therapeutic potential of psilocybin for various conditions, including end-of-life anxiety, obsessive-compulsive disorder, and smoking and alcohol dependence, with promising preliminary results. Here, we aimed to investigate the feasibility, safety, and efficacy of psilocybin in patients with unipolar treatment-re…
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression
Introduction: It is a basic principle of the ‘psychedelic’ treatment model that the quality of the acute experience mediates long-term improvements in mental health. In the present paper we sought to test this using data from a clinical trial assessing psilocybin for treatment-resistant depression (TRD). In line with previous reports, we hypothesized that the occurrence and magnitude of Oceanic Boundlessness (OBN) (sharing features with mystical-…
Using Baclofen to Explore Gaba-B Receptor Function in Alcohol Dependence: Insights From Pharmacokinetic and Pharmacodynamic Measures
Background: The role of GABA-B neurotransmission in addiction has recently received increased attention, with clinical trials indicating that baclofen, a GABA-B receptor agonist, may reduce alcohol consumption, craving and promote abstinence. However, the optimal dose to treat alcohol dependence is unclear with patients requesting and tolerating much higher doses of baclofen, compared with other clinical uses. We assessed the pharmacokinetics and…
A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation
The MCDA process allowed the participants to deconstruct complex drug policy issues into a set of simpler judgements that led to consensus about the results
Acute nutritional state and Body Mass Index influence Anterior Cingulate Cortex activation during motor response inhibition
Do Gut Hormones attenuate eating and addictive behaviours in obesity, alcohol and nicotine dependence
Trial of Psilocybin versus Escitalopram for Depression
BACKGROUND: Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. METHODS: In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Patients were assigned in a 1:1 ratio…
Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”
Background: Anorexia nervosa (AN) is a serious and life-threatening psychiatric condition. With a paucity of approved treatments, there is a desperate need for novel treatment avenues to be explored. Here, we present (1) an overview of the ways through which Public Patient Involvement (PPI) has informed a trial of psilocybin-assisted therapy for AN and (2) a protocol for a pilot study of psilocybin-assisted therapy in AN currently underway at Imp…
A multi criteria decision analysis (MCDA) for evaluating and appraising government policy responses to non medical heroin use
Comparison of food cue reactivity and eating behaviours in obesity, ex-smokers and abstinent alcohol dependence
Selective D3 receptor antagonism modulates neural response during negative emotional processing in substance dependence
Acute GSK598809 modulates the BOLD response to aversive image processing, providing evidence that D3 antagonism may impact emotional regulation. Enhanced BOLD response within D3-rich mesolimbic regions is consistent with its pharmacology and with attenuation of substance-related hypodopaminergic function. However, the lack of group differences in task-related BOLD response and the non-specific effect of GSK598809 between groups makes it difficult…
Comparison of food cue reactivity and eating behaviours in obesity, ex-smokers and abstinent alcohol dependence
Psychedelics As Psychiatric Medications
Study protocol for “Psilocybin in patients with fibromyalgia: Brain biomarkers of action”
The results of this study will provide valuable insight into the brain mechanisms involved in the action of psilocybin-therapy for fibromyalgia with potential implications for the therapeutic action of psychedelic-therapy more broadly. It will also deliver essential data to inform the design of a potential subsequent RCT
Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder
The mechanisms by which Psilocybin Therapy (PT) improves depression remain an important object of study, with scientists actively exploring acute psychological experiences and neurobiological processes as candidates. In a phase 2, double-blind, randomized, active comparator controlled trial involving patients with moderate-to-severe major depressive disorder, we investigated whether acute psychological experiences could meaningfully account for t…
Medicine (19 works) · Psychology (19 works) · Psychiatry (18 works) · Hallucinogen (8 works) · Psilocybin (8 works) · Psychedelics and Drug Studies (8 works) · Internal Medicine (6 works) · Neurotransmitter Receptor Influence on Behavior (6 works) · Addiction (5 works) · Alcohol (5 works)